Author: Ravi Shankar

As the UK accelerates efforts to improve the energy performance of its building stock and achieve its Net Zero ambitions, Sisecam’s latest research shows that high-performance glazing can play a significant role in reducing energy consumption, cutting carbon emissions and enabling more effective building renovation programmes

ISTANBUL, Nov. 13, 2026 (GLOBE NEWSWIRE) — Sisecam, the only global player operating in all core areas of glass, participated in the 31st United Nations Climate Change Conference (COP31), held in Antalya from 9–20 November, as a Climate Supporter. At COP31, the company highlighted the role of advanced glass technologies in improving energy efficiency, supporting decarbonization and helping cities adapt to the impacts of climate change.

As countries work to accelerate the transition to a low-carbon economy, improving the energy performance of existing buildings remains a critical challenge. While decarbonizing energy generation is essential, reducing energy demand in the buildings where people live, and work is equally important. High-performance building materials can play a significant role in lowering energy consumption, reducing emissions and supporting long-term climate objectives.

A study developed by Sisecam and METU-GÜNAM (Middle East Technical University Center for Solar Energy Research and Applications) examined the impact of different glazing configurations on energy consumption and emissions in residential buildings under varying climate conditions. Using advanced simulations and long-term projections through 2050, the research evaluated how glass technologies can help improve building performance and support climate goals.

High-performance glazing can deliver significant emissions reductions

According to the study, the large-scale use of solar-control triple glazing with low-emissivity (Low-E) coatings across Istanbul’s residential building stock could avoid an estimated 13.1 million tons of operational CO₂ emissions cumulatively by 2050 under the SSP5-8.5 scenario, equivalent to approximately 4.4% of cumulative operational emissions from the buildings analysed.

The research highlights that glazing performance can play an increasingly important role in reducing energy demand while improving indoor comfort. By limiting unwanted solar heat gains during warmer periods and enhancing thermal insulation throughout the year, advanced glazing systems can help reduce both cooling and heating requirements.

Building performance is critical to achieving climate goals

One of the key findings of the study is that building energy needs are evolving as climate conditions change. While heating demand is expected to decline over time, cooling requirements are projected to increase significantly, making building-envelope performance more critical than ever.

The research demonstrates that high-performance glass can help manage this changing balance by reducing overheating during warmer periods while maintaining effective thermal insulation throughout the year. This contributes not only to lower energy consumption and emissions but also to greater occupant comfort and building resilience.

Targeted renovation can maximize impact

The study also highlights the value of targeted renovation strategies. Rather than applying interventions uniformly across the building stock, prioritizing buildings with the least efficient glazing and the highest saving potential can significantly improve investment effectiveness. For the best-performing zones analysed, the abatement cost falls to approximately EUR 11 per ton of CO₂ avoided, while less than 5% of the total investment delivers around 11% of the achievable emissions savings.

These findings underline the importance of data-driven renovation programmes and climate-specific glazing requirements in maximizing both environmental impact and economic efficiency.

Supporting the UK’s Net Zero and building-renovation ambitions

The UK’s building stock will play a crucial role in achieving national climate targets. While the study was conducted using Istanbul’s residential building stock as a model, its findings provide valuable insights for markets facing similar building-renovation and decarbonization challenges. As policymakers, investors and property owners seek to improve energy efficiency, reduce emissions and upgrade ageing buildings, the findings offer valuable insights into the role advanced glass technologies can play in supporting these efforts.

The study suggests that renovation programmes can achieve greater environmental and economic benefits when interventions are tailored to building characteristics and local climate conditions. High-performance glazing can help lower energy demand, improve indoor comfort and support long-term decarbonization goals, particularly in buildings with inefficient existing windows.

The findings also reinforce the importance of prioritizing renovation measures that deliver the greatest emissions reductions and energy savings, helping maximize the effectiveness of investment in the built environment.

Commenting on the findings, Can Yücel, CEO of Sisecam, said:

“Reaching climate goals requires improving not only how energy is generated, but also how it is consumed. Existing buildings represent one of the greatest opportunities to reduce energy demand and emissions. At Sisecam, we believe high-performance glass can play an important role in supporting building decarbonization while improving comfort and energy efficiency. Through our collaboration with METU-GÜNAM, we aim to provide data-driven insights that can help inform more effective renovation strategies and accelerate the transition to a low-carbon built environment.”

Methodological note

The research uses EnergyPlus- an open-source building energy and water simulation engine developed by the U.S. Department of Energy- to simulate the effects of different glazing configurations. The city-scale analysis begins with a model calibrated using 2,455 residential buildings in Kadıköy (a district in İstanbul) and scales the findings to the building stock of Istanbul’s 39 other districts, assuming comparable performance for buildings within the same categories. The simulations isolate the effects of changing the glazing while keeping all other parameters constant. The emissions considered are operational emissions associated with building energy consumption and do not cover the products’ full life cycle. The study uses a 2025 baseline and considers two future scenarios to 2050: SSP5-8.5 and SSP2-4.5, incorporating different assumptions for climate change, electricity grid decarbonization, energy prices and discount rates.

About Sisecam

Sisecam is a story of progress…

Founded in 1935 by İş Bankası with the vision, Sisecam was established to build Türkiye’s glass industry. Over the decades, Sisecam has grown from a local initiative into a global player in glass and chemicals. As the only global company operating in all core areas of glass production, Sisecam is one of the world’s top five producers in its sectors. Sisecam operates across four continents and 13 countries, including Türkiye, Italy, Bulgaria, Romania, Slovakia, Hungary, Bosnia and Herzegovina, Russia, Georgia, Ukraine, Egypt, India, and the United States. Sisecam plays a pioneering role in flat glass, glassware, glass packaging, chemicals, auto glass, glass fiber, mining, energy, and recycling industries. By placing innovation and technology at the core of its operations, Sisecam delivers its products to customers in over 150 countries through its robust supply chain.

Sisecam makes a meaningful difference in its industries with 90 years of expertise, a skilled workforce, and the use of smart technologies. Supported by almost 23,000 employees, Sisecam is steadily advancing toward its goal of becoming one of the top three global producers in its core industries. With its CareForNext strategy, Sisecam works to ensure the sustainability of the glass and chemicals industries from the perspectives of protecting the planet, empowering communities, and transforming lives in line with the United Nations Sustainable Development Goals. Sisecam is pursuing a better future through technology and innovation and continues its story of progress together with its entire ecosystem.

Learn more: www.sisecam.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/25ec938c-9413-44b5-99ea-a32fa94518dc

CONTACT: Ayşegül Akyarlı
AAKYARLI@sisecam.com

As the UK accelerates efforts to improve the energy performance of its building stock and achieve its Net Zero ambitions, Sisecam’s latest research shows that high-performance glazing can play a significant role in reducing energy consumption, cutting carbon emissions and enabling more effective building renovation programmes

ISTANBUL, Nov. 13, 2026 (GLOBE NEWSWIRE) — Sisecam, the only global player operating in all core areas of glass, participated in the 31st United Nations Climate Change Conference (COP31), held in Antalya from 9–20 November, as a Climate Supporter. At COP31, the company highlighted the role of advanced glass technologies in improving energy efficiency, supporting decarbonization and helping cities adapt to the impacts of climate change.

As countries work to accelerate the transition to a low-carbon economy, improving the energy performance of existing buildings remains a critical challenge. While decarbonizing energy generation is essential, reducing energy demand in the buildings where people live, and work is equally important. High-performance building materials can play a significant role in lowering energy consumption, reducing emissions and supporting long-term climate objectives.

A study developed by Sisecam and METU-GÜNAM (Middle East Technical University Center for Solar Energy Research and Applications) examined the impact of different glazing configurations on energy consumption and emissions in residential buildings under varying climate conditions. Using advanced simulations and long-term projections through 2050, the research evaluated how glass technologies can help improve building performance and support climate goals.

High-performance glazing can deliver significant emissions reductions

According to the study, the large-scale use of solar-control triple glazing with low-emissivity (Low-E) coatings across Istanbul’s residential building stock could avoid an estimated 13.1 million tons of operational CO₂ emissions cumulatively by 2050 under the SSP5-8.5 scenario, equivalent to approximately 4.4% of cumulative operational emissions from the buildings analysed.

The research highlights that glazing performance can play an increasingly important role in reducing energy demand while improving indoor comfort. By limiting unwanted solar heat gains during warmer periods and enhancing thermal insulation throughout the year, advanced glazing systems can help reduce both cooling and heating requirements.

Building performance is critical to achieving climate goals

One of the key findings of the study is that building energy needs are evolving as climate conditions change. While heating demand is expected to decline over time, cooling requirements are projected to increase significantly, making building-envelope performance more critical than ever.

The research demonstrates that high-performance glass can help manage this changing balance by reducing overheating during warmer periods while maintaining effective thermal insulation throughout the year. This contributes not only to lower energy consumption and emissions but also to greater occupant comfort and building resilience.

Targeted renovation can maximize impact

The study also highlights the value of targeted renovation strategies. Rather than applying interventions uniformly across the building stock, prioritizing buildings with the least efficient glazing and the highest saving potential can significantly improve investment effectiveness. For the best-performing zones analysed, the abatement cost falls to approximately EUR 11 per ton of CO₂ avoided, while less than 5% of the total investment delivers around 11% of the achievable emissions savings.

These findings underline the importance of data-driven renovation programmes and climate-specific glazing requirements in maximizing both environmental impact and economic efficiency.

Supporting the UK’s Net Zero and building-renovation ambitions

The UK’s building stock will play a crucial role in achieving national climate targets. While the study was conducted using Istanbul’s residential building stock as a model, its findings provide valuable insights for markets facing similar building-renovation and decarbonization challenges. As policymakers, investors and property owners seek to improve energy efficiency, reduce emissions and upgrade ageing buildings, the findings offer valuable insights into the role advanced glass technologies can play in supporting these efforts.

The study suggests that renovation programmes can achieve greater environmental and economic benefits when interventions are tailored to building characteristics and local climate conditions. High-performance glazing can help lower energy demand, improve indoor comfort and support long-term decarbonization goals, particularly in buildings with inefficient existing windows.

The findings also reinforce the importance of prioritizing renovation measures that deliver the greatest emissions reductions and energy savings, helping maximize the effectiveness of investment in the built environment.

Commenting on the findings, Can Yücel, CEO of Sisecam, said:

“Reaching climate goals requires improving not only how energy is generated, but also how it is consumed. Existing buildings represent one of the greatest opportunities to reduce energy demand and emissions. At Sisecam, we believe high-performance glass can play an important role in supporting building decarbonization while improving comfort and energy efficiency. Through our collaboration with METU-GÜNAM, we aim to provide data-driven insights that can help inform more effective renovation strategies and accelerate the transition to a low-carbon built environment.”

Methodological note

The research uses EnergyPlus- an open-source building energy and water simulation engine developed by the U.S. Department of Energy- to simulate the effects of different glazing configurations. The city-scale analysis begins with a model calibrated using 2,455 residential buildings in Kadıköy (a district in İstanbul) and scales the findings to the building stock of Istanbul’s 39 other districts, assuming comparable performance for buildings within the same categories. The simulations isolate the effects of changing the glazing while keeping all other parameters constant. The emissions considered are operational emissions associated with building energy consumption and do not cover the products’ full life cycle. The study uses a 2025 baseline and considers two future scenarios to 2050: SSP5-8.5 and SSP2-4.5, incorporating different assumptions for climate change, electricity grid decarbonization, energy prices and discount rates.

About Sisecam

Sisecam is a story of progress…

Founded in 1935 by İş Bankası with the vision, Sisecam was established to build Türkiye’s glass industry. Over the decades, Sisecam has grown from a local initiative into a global player in glass and chemicals. As the only global company operating in all core areas of glass production, Sisecam is one of the world’s top five producers in its sectors. Sisecam operates across four continents and 13 countries, including Türkiye, Italy, Bulgaria, Romania, Slovakia, Hungary, Bosnia and Herzegovina, Russia, Georgia, Ukraine, Egypt, India, and the United States. Sisecam plays a pioneering role in flat glass, glassware, glass packaging, chemicals, auto glass, glass fiber, mining, energy, and recycling industries. By placing innovation and technology at the core of its operations, Sisecam delivers its products to customers in over 150 countries through its robust supply chain.

Sisecam makes a meaningful difference in its industries with 90 years of expertise, a skilled workforce, and the use of smart technologies. Supported by almost 23,000 employees, Sisecam is steadily advancing toward its goal of becoming one of the top three global producers in its core industries. With its CareForNext strategy, Sisecam works to ensure the sustainability of the glass and chemicals industries from the perspectives of protecting the planet, empowering communities, and transforming lives in line with the United Nations Sustainable Development Goals. Sisecam is pursuing a better future through technology and innovation and continues its story of progress together with its entire ecosystem.

Learn more: www.sisecam.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/25ec938c-9413-44b5-99ea-a32fa94518dc

CONTACT: Ayşegül Akyarlı
AAKYARLI@sisecam.com

TORONTO, Nov. 13, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum” or the “Company“) reports its unaudited financial and operational results for the third quarter ended September 30, 2026.

As of September 30, 2026, cash and cash equivalents totaled approximately US$3.56 million and digital assets totaled approximately US$8.66 million, representing combined holdings of approximately US$12.22 million, compared with US$4.12 million as of December 31, 2025 (excluding US$1.60 million of digital assets that were restricted at that date). Total shareholders’ equity increased approximately 91% to US$9.77 million, from US$5.10 million at December 31, 2025.

Subsequent to quarter-end, the Company entered into a Study Start-Up Agreement with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-MS in progressive multiple sclerosis, following the clearance of its Investigational New Drug application by the U.S. Food and Drug Administration (FDA) in August 2026.

Third Quarter 2026 Financial Results

Quantum reduced operating expenses year over year while increasing total assets, cash holdings and shareholders’ equity. Management has concluded that the Company’s cash and cash equivalents and digital assets as of September 30, 2026 are sufficient to carry out its planned operations over the next twelve months.

Liquidity and Balance Sheet Strength

• Cash and cash equivalents and digital assets totaled approximately US$12.22 million as of September 30, 2026, compared with US$4.12 million at December 31, 2025 (excluding US$1.60 million of restricted digital assets at that date).
• Cash and cash equivalents increased approximately 87% to US$3.56 million, from US$1.91 million at December 31, 2025.
• Digital assets increased approximately 127% to US$8.66 million, from US$3.82 million at December 31, 2025 (restricted and unrestricted). No digital assets were restricted as of September 30, 2026.
• Total shareholders’ equity increased approximately 91% to US$9.77 million, from US$5.10 million at December 31, 2025.
• Total assets increased approximately 55% to US$17.33 million, from US$11.16 million at December 31, 2025.
• Working capital increased to approximately US$5.47 million as of September 30, 2026, compared with approximately US$0.42 million at December 31, 2025.
• Notes payable decreased to US$0.30 million, from US$1.30 million at December 31, 2025, following the repayment of US$1.00 million of the BitGo loan during the nine months ended September 30, 2026.

Key Financial Ratios (as of September 30, 2026)

• Current ratio of 1.72 as of September 30, 2026, compared to 1.07 as of December 31, 2025.
• Debt-to-Equity ratio of 0.77 as of September 30, 2026, compared to 1.19 as of December 31, 2025. Total liabilities were approximately US$7.56 million as of September 30, 2026, compared with US$6.06 million at December 31, 2025. Approximately 38% of current liabilities as of September 30, 2026 are non-cash fair-value items, being US$2.17 million of warrant liabilities and US$0.68 million of derivative liabilities.
• Equity represented approximately 56% of total assets as of September 30, 2026, compared with 46% as of December 31, 2025.

Reduced Operating Expenses and Cash Use

• Total operating expenses decreased approximately 24% in the third quarter of 2026, to US$3.56 million from US$4.68 million in the third quarter of 2025. For the nine months ended September 30, 2026, total operating expenses decreased approximately 32%, to US$8.81 million from US$12.93 million.
• Cash used in operating activities decreased approximately 21%, to US$6.25 million for the nine months ended September 30, 2026 from US$7.93 million for the comparable 2025 period.
• Net loss for the nine months ended September 30, 2026 was US$17.32 million, compared with US$23.25 million for the nine months ended September 30, 2025, a decrease of approximately 26%. The nine-month result includes an unrealized gain of US$0.64 million on the change in fair value of digital assets.

Third Quarter and Subsequent 2026 Corporate Highlights

Lucid-MS Phase 2 Trial: FDA Clearance and Study Start-Up Agreement with Thermo Fisher Scientific

On August 10, 2026, the Company announced that the FDA had cleared its Investigational New Drug (IND) application for Lucid-MS (Lucid-21-302), enabling the Company to proceed with a randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with progressive multiple sclerosis.

Subsequent to quarter-end, on October 6, 2026, the Company entered into a Study Start-Up Agreement with the clinical research business of Thermo Fisher Scientific to implement the Phase 2 clinical trial of Lucid-MS, marking the initiation of formal study start-up activities. The trial will evaluate the efficacy, safety and tolerability of Lucid-MS in people with progressive forms of multiple sclerosis.

Unbuzzd

On September 24, 2026, Unbuzzd announced the appointment of Michael Zapolin as Chief Executive Officer, with a mandate that includes financing Unbuzzd, listing it on a stock exchange and executing a nationwide commercial rollout in the United States. Subsequent to quarter-end, on October 13, 2026, the Company and Unbuzzd extended the maturity of the Company’s loan to Unbuzzd to December 31, 2027, and on October 15, 2026 the Company subscribed for 1,500,000 common shares of Unbuzzd at C$0.20 per share under Unbuzzd’s private placement. Following the placement, the Company held a 19.87% ownership interest in Unbuzzd.

Management Commentary

“With FDA clearance in hand and our Study Start-Up Agreement signed with the clinical research business of Thermo Fisher Scientific, Lucid-MS has moved from planning into the implementation of its Phase 2 trial in progressive multiple sclerosis,” said Zeeshan Saeed, Chief Executive Officer of Quantum.

“Shareholders’ equity has grown 91% since the start of the year to US$9.77 million, and working capital now stands at US$5.47 million, while we reduced total operating expenses by 32% over the first nine months of 2026 compared with the same period last year,” said Donal Carroll, Chief Financial Officer of Quantum.

About Quantum BioPharma Ltd.

Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.87% (as of November 12, 2026) of Unbuzzd at www.unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

Forward Looking Information

Certain statements contained in this news release constitute “forward-looking information” within the meaning of applicable Canadian securities legislation and “forward-looking statements” within the meaning of applicable United States securities laws (collectively, “forward-looking statements”). All statements other than statements of historical fact may constitute forward-looking statements. Forward-looking statements are often, but not always, identified by words or phrases such as “may,” “should,” “anticipate,” “expect,” “potential,” “believe,” “intend,” “plan,” “estimate,” “project,” “continue,” “will” and similar expressions, including the negatives thereof.

Forward-looking statements contained in this news release include, but are not limited to, statements regarding: the sufficiency of the Company’s cash and cash equivalents and digital assets to carry out its planned operations over the next twelve months; the anticipated initiation, timing, design, conduct and progress of the Company’s planned Lucid-MS Phase 2 clinical trial, including study start-up activities; future regulatory interactions, submissions and approvals relating to Lucid-MS; the continued clinical development, therapeutic potential, safety and efficacy of Lucid-MS (Lucid-21-302); and the anticipated financing, stock exchange listing and commercialization of Unbuzzd.

The forward-looking statements contained in this news release are based on management’s current expectations, estimates, projections, assumptions and beliefs as of the date of this news release. With respect to the sufficiency of the Company’s cash and cash equivalents and digital assets, material assumptions include, among others, that the Company’s cash burn and operating expenditures will remain generally consistent with management’s current budget and the cash burn rate experienced during the first nine months of 2026; that the Company’s existing cash, cash equivalents and digital assets will remain available to fund planned operations; that there will be no material adverse changes in the value or liquidity of the Company’s digital assets; and that the Company will not incur material unanticipated expenditures or experience material changes to the timing or cost of its planned clinical development activities. Other material assumptions include the Company’s ability to advance Lucid-MS through clinical development substantially in accordance with its current plans; the availability of sufficient personnel, resources and clinical trial sites; successful patient enrollment and retention; and constructive interactions with regulatory authorities.

Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, but are not limited to: changes in the Company’s operating costs or cash burn rate; fluctuations in the value or liquidity of digital assets; the need for additional financing and the Company’s ability to obtain such financing on acceptable terms or at all; risks associated with the timing, initiation, conduct, enrollment, retention, cost and results of clinical trials; the possibility of delays or changes in the Company’s clinical development plans; uncertainty regarding future regulatory submissions, interactions, reviews and approvals; the possibility that clinical trial results may not demonstrate the anticipated safety or efficacy of Lucid-MS; and other risks associated with the Company’s business and operations generally.

Readers are cautioned that the foregoing list of risks and assumptions is not exhaustive. Additional information concerning risks and uncertainties affecting Quantum BioPharma is contained in the Company’s continuous disclosure filings, including its most recent annual information form and other filings available under the Company’s profile on SEDAR+ and through the EDGAR system of the U.S. Securities and Exchange Commission.

Readers are cautioned not to place undue reliance on forward-looking statements. Although the Company believes that the expectations and assumptions reflected in such forward-looking statements are reasonable as of the date hereof, there can be no assurance that such expectations will prove to be correct. Actual results and future events could differ materially from those anticipated in such statements.

The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date of this news release. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (833) 571-1811

Investor Relations
Email: ir@quantumbiopharma.com, info@quantumbiopharma.com
Website: www.quantumbiopharma.com

TORONTO, Nov. 13, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum” or the “Company“) reports its unaudited financial and operational results for the third quarter ended September 30, 2026.

As of September 30, 2026, cash and cash equivalents totaled approximately US$3.56 million and digital assets totaled approximately US$8.66 million, representing combined holdings of approximately US$12.22 million, compared with US$4.12 million as of December 31, 2025 (excluding US$1.60 million of digital assets that were restricted at that date). Total shareholders’ equity increased approximately 91% to US$9.77 million, from US$5.10 million at December 31, 2025.

Subsequent to quarter-end, the Company entered into a Study Start-Up Agreement with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-MS in progressive multiple sclerosis, following the clearance of its Investigational New Drug application by the U.S. Food and Drug Administration (FDA) in August 2026.

Third Quarter 2026 Financial Results

Quantum reduced operating expenses year over year while increasing total assets, cash holdings and shareholders’ equity. Management has concluded that the Company’s cash and cash equivalents and digital assets as of September 30, 2026 are sufficient to carry out its planned operations over the next twelve months.

Liquidity and Balance Sheet Strength

• Cash and cash equivalents and digital assets totaled approximately US$12.22 million as of September 30, 2026, compared with US$4.12 million at December 31, 2025 (excluding US$1.60 million of restricted digital assets at that date).
• Cash and cash equivalents increased approximately 87% to US$3.56 million, from US$1.91 million at December 31, 2025.
• Digital assets increased approximately 127% to US$8.66 million, from US$3.82 million at December 31, 2025 (restricted and unrestricted). No digital assets were restricted as of September 30, 2026.
• Total shareholders’ equity increased approximately 91% to US$9.77 million, from US$5.10 million at December 31, 2025.
• Total assets increased approximately 55% to US$17.33 million, from US$11.16 million at December 31, 2025.
• Working capital increased to approximately US$5.47 million as of September 30, 2026, compared with approximately US$0.42 million at December 31, 2025.
• Notes payable decreased to US$0.30 million, from US$1.30 million at December 31, 2025, following the repayment of US$1.00 million of the BitGo loan during the nine months ended September 30, 2026.

Key Financial Ratios (as of September 30, 2026)

• Current ratio of 1.72 as of September 30, 2026, compared to 1.07 as of December 31, 2025.
• Debt-to-Equity ratio of 0.77 as of September 30, 2026, compared to 1.19 as of December 31, 2025. Total liabilities were approximately US$7.56 million as of September 30, 2026, compared with US$6.06 million at December 31, 2025. Approximately 38% of current liabilities as of September 30, 2026 are non-cash fair-value items, being US$2.17 million of warrant liabilities and US$0.68 million of derivative liabilities.
• Equity represented approximately 56% of total assets as of September 30, 2026, compared with 46% as of December 31, 2025.

Reduced Operating Expenses and Cash Use

• Total operating expenses decreased approximately 24% in the third quarter of 2026, to US$3.56 million from US$4.68 million in the third quarter of 2025. For the nine months ended September 30, 2026, total operating expenses decreased approximately 32%, to US$8.81 million from US$12.93 million.
• Cash used in operating activities decreased approximately 21%, to US$6.25 million for the nine months ended September 30, 2026 from US$7.93 million for the comparable 2025 period.
• Net loss for the nine months ended September 30, 2026 was US$17.32 million, compared with US$23.25 million for the nine months ended September 30, 2025, a decrease of approximately 26%. The nine-month result includes an unrealized gain of US$0.64 million on the change in fair value of digital assets.

Third Quarter and Subsequent 2026 Corporate Highlights

Lucid-MS Phase 2 Trial: FDA Clearance and Study Start-Up Agreement with Thermo Fisher Scientific

On August 10, 2026, the Company announced that the FDA had cleared its Investigational New Drug (IND) application for Lucid-MS (Lucid-21-302), enabling the Company to proceed with a randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with progressive multiple sclerosis.

Subsequent to quarter-end, on October 6, 2026, the Company entered into a Study Start-Up Agreement with the clinical research business of Thermo Fisher Scientific to implement the Phase 2 clinical trial of Lucid-MS, marking the initiation of formal study start-up activities. The trial will evaluate the efficacy, safety and tolerability of Lucid-MS in people with progressive forms of multiple sclerosis.

Unbuzzd

On September 24, 2026, Unbuzzd announced the appointment of Michael Zapolin as Chief Executive Officer, with a mandate that includes financing Unbuzzd, listing it on a stock exchange and executing a nationwide commercial rollout in the United States. Subsequent to quarter-end, on October 13, 2026, the Company and Unbuzzd extended the maturity of the Company’s loan to Unbuzzd to December 31, 2027, and on October 15, 2026 the Company subscribed for 1,500,000 common shares of Unbuzzd at C$0.20 per share under Unbuzzd’s private placement. Following the placement, the Company held a 19.87% ownership interest in Unbuzzd.

Management Commentary

“With FDA clearance in hand and our Study Start-Up Agreement signed with the clinical research business of Thermo Fisher Scientific, Lucid-MS has moved from planning into the implementation of its Phase 2 trial in progressive multiple sclerosis,” said Zeeshan Saeed, Chief Executive Officer of Quantum.

“Shareholders’ equity has grown 91% since the start of the year to US$9.77 million, and working capital now stands at US$5.47 million, while we reduced total operating expenses by 32% over the first nine months of 2026 compared with the same period last year,” said Donal Carroll, Chief Financial Officer of Quantum.

About Quantum BioPharma Ltd.

Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.87% (as of November 12, 2026) of Unbuzzd at www.unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

Forward Looking Information

Certain statements contained in this news release constitute “forward-looking information” within the meaning of applicable Canadian securities legislation and “forward-looking statements” within the meaning of applicable United States securities laws (collectively, “forward-looking statements”). All statements other than statements of historical fact may constitute forward-looking statements. Forward-looking statements are often, but not always, identified by words or phrases such as “may,” “should,” “anticipate,” “expect,” “potential,” “believe,” “intend,” “plan,” “estimate,” “project,” “continue,” “will” and similar expressions, including the negatives thereof.

Forward-looking statements contained in this news release include, but are not limited to, statements regarding: the sufficiency of the Company’s cash and cash equivalents and digital assets to carry out its planned operations over the next twelve months; the anticipated initiation, timing, design, conduct and progress of the Company’s planned Lucid-MS Phase 2 clinical trial, including study start-up activities; future regulatory interactions, submissions and approvals relating to Lucid-MS; the continued clinical development, therapeutic potential, safety and efficacy of Lucid-MS (Lucid-21-302); and the anticipated financing, stock exchange listing and commercialization of Unbuzzd.

The forward-looking statements contained in this news release are based on management’s current expectations, estimates, projections, assumptions and beliefs as of the date of this news release. With respect to the sufficiency of the Company’s cash and cash equivalents and digital assets, material assumptions include, among others, that the Company’s cash burn and operating expenditures will remain generally consistent with management’s current budget and the cash burn rate experienced during the first nine months of 2026; that the Company’s existing cash, cash equivalents and digital assets will remain available to fund planned operations; that there will be no material adverse changes in the value or liquidity of the Company’s digital assets; and that the Company will not incur material unanticipated expenditures or experience material changes to the timing or cost of its planned clinical development activities. Other material assumptions include the Company’s ability to advance Lucid-MS through clinical development substantially in accordance with its current plans; the availability of sufficient personnel, resources and clinical trial sites; successful patient enrollment and retention; and constructive interactions with regulatory authorities.

Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, but are not limited to: changes in the Company’s operating costs or cash burn rate; fluctuations in the value or liquidity of digital assets; the need for additional financing and the Company’s ability to obtain such financing on acceptable terms or at all; risks associated with the timing, initiation, conduct, enrollment, retention, cost and results of clinical trials; the possibility of delays or changes in the Company’s clinical development plans; uncertainty regarding future regulatory submissions, interactions, reviews and approvals; the possibility that clinical trial results may not demonstrate the anticipated safety or efficacy of Lucid-MS; and other risks associated with the Company’s business and operations generally.

Readers are cautioned that the foregoing list of risks and assumptions is not exhaustive. Additional information concerning risks and uncertainties affecting Quantum BioPharma is contained in the Company’s continuous disclosure filings, including its most recent annual information form and other filings available under the Company’s profile on SEDAR+ and through the EDGAR system of the U.S. Securities and Exchange Commission.

Readers are cautioned not to place undue reliance on forward-looking statements. Although the Company believes that the expectations and assumptions reflected in such forward-looking statements are reasonable as of the date hereof, there can be no assurance that such expectations will prove to be correct. Actual results and future events could differ materially from those anticipated in such statements.

The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date of this news release. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (833) 571-1811

Investor Relations
Email: ir@quantumbiopharma.com, info@quantumbiopharma.com
Website: www.quantumbiopharma.com

HOUSTON, Nov. 13, 2026 (GLOBE NEWSWIRE) — Weatherford International Corp (NASDAQ: WFRD) (“Weatherford” or the “Company”) today announced that it has completed its previously announced redomestication from Ireland to Delaware. As a result of the redomestication, the Company expects to generate approximately $20 million to $30 million in annual cash savings beginning in 2027.

The redomestication was completed through a scheme of arrangement under Irish law. As a result, Weatherford International Corp, a Delaware corporation, has become the publicly traded parent company of the Weatherford group.

Each outstanding ordinary share of Weatherford International plc was cancelled in exchange for a share of common stock of Weatherford International Corp on a one-for-one basis. Weatherford’s common stock will continue to trade on the Nasdaq Global Select Market under the ticker symbol “WFRD.”

The redomestication does not change Weatherford’s business operations, management, strategy or headquarters. The Company’s directors and executive officers will continue in their respective roles with Weatherford International Corp.

Girish Saligram, Weatherford’s President and Chief Executive Officer, commented, “The completion of our redomestication represents another deliberate step in positioning Weatherford for long-term success. We have built a stronger, more focused and more resilient Company, and this move further simplifies our structure as we continue to execute our strategy. Our focus remains on delivering differentiated value for our customers, maintaining disciplined capital allocation and driving sustainable shareholder returns.”

In connection with the redomestication, Weatherford’s Board of Directors adopted and assumed the Company’s existing capital return program, including the remaining authorization under its share repurchase program through June 2027 and the intent to continue paying regular quarterly cash dividends. The timing and amount of any share repurchases and future dividends will remain subject to applicable legal requirements, market and business conditions and the discretion of the Board of Directors.

Additional information regarding the redomestication is available in Weatherford’s filings with the U.S. Securities and Exchange Commission.

About Weatherford

Weatherford is a global energy services company that helps customers drill smarter, complete wells more effectively, and maximize production across the entire well lifecycle. With a differentiated portfolio of market-leading solutions, integrated technologies, and a broad global customer footprint across six continents, we blend advanced engineering, digital intelligence, and world-class field expertise to reduce risk, improve performance, and maximize the value of customer assets. Together, we elevate every operation, delivering stronger wells, sharper decisions, and better energy for the world. Visit weatherford.com for more information and connect with us on social media.

Forward-Looking Statements

This release, as well as other statements we make, includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements that are not historical facts, including statements about Weatherford’s beliefs, plans, estimates, or expectations, are forward-looking statements. Forward-looking statements often use words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “plan,” “potential,” “should,” “target,” “will,” and other words of similar meaning. Such forward-looking statements include, but are not limited to, statements regarding the Redomestication, the related restructuring activities and the expected timing and financial implications. These statements are based on current beliefs, plans, estimates, and expectations, all of which involve risk and uncertainty. Actual results may differ materially from those included in such forward-looking statements and therefore you should not place undue reliance on them.

The factors that could cause actual results to differ materially from current expectations include, but are not limited to, our ability to realize the expected benefits from the Redomestication; the occurrence of difficulties in connection with the Redomestication, including any costs related thereto; the risk that the Redomestication disrupts current plans and operations; any changes in tax laws, tax treaties or tax regulations or the interpretation or enforcement thereof by the tax authorities in Ireland, the United States and other jurisdictions following the Redomestication; and the future financial performance of Weatherford following the Redomestication.

The foregoing factors are in addition to those other risks, uncertainties, and factors included in the “Risk Factors” section and elsewhere in Weatherford’s reports filed with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and other documents filed with the SEC. There may be other risks and uncertainties that we are not currently aware of or are unable to predict and which may also affect Weatherford’s forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements made in this communication are made only as of the date hereof or as of the dates indicated in the forward-looking statements and Weatherford undertakes no obligation to update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.

For Investors:
Luke Lemoine
Senior Vice President, Corporate Development & Investor Relations
+1 713-836-7777
investor.relations@weatherford.com

For Media:
Kelley Hughes
Vice President, Communications, Marketing & Sustainability
media@weatherford.com

HOUSTON, Nov. 13, 2026 (GLOBE NEWSWIRE) — Weatherford International Corp (NASDAQ: WFRD) (“Weatherford” or the “Company”) today announced that it has completed its previously announced redomestication from Ireland to Delaware. As a result of the redomestication, the Company expects to generate approximately $20 million to $30 million in annual cash savings beginning in 2027.

The redomestication was completed through a scheme of arrangement under Irish law. As a result, Weatherford International Corp, a Delaware corporation, has become the publicly traded parent company of the Weatherford group.

Each outstanding ordinary share of Weatherford International plc was cancelled in exchange for a share of common stock of Weatherford International Corp on a one-for-one basis. Weatherford’s common stock will continue to trade on the Nasdaq Global Select Market under the ticker symbol “WFRD.”

The redomestication does not change Weatherford’s business operations, management, strategy or headquarters. The Company’s directors and executive officers will continue in their respective roles with Weatherford International Corp.

Girish Saligram, Weatherford’s President and Chief Executive Officer, commented, “The completion of our redomestication represents another deliberate step in positioning Weatherford for long-term success. We have built a stronger, more focused and more resilient Company, and this move further simplifies our structure as we continue to execute our strategy. Our focus remains on delivering differentiated value for our customers, maintaining disciplined capital allocation and driving sustainable shareholder returns.”

In connection with the redomestication, Weatherford’s Board of Directors adopted and assumed the Company’s existing capital return program, including the remaining authorization under its share repurchase program through June 2027 and the intent to continue paying regular quarterly cash dividends. The timing and amount of any share repurchases and future dividends will remain subject to applicable legal requirements, market and business conditions and the discretion of the Board of Directors.

Additional information regarding the redomestication is available in Weatherford’s filings with the U.S. Securities and Exchange Commission.

About Weatherford

Weatherford is a global energy services company that helps customers drill smarter, complete wells more effectively, and maximize production across the entire well lifecycle. With a differentiated portfolio of market-leading solutions, integrated technologies, and a broad global customer footprint across six continents, we blend advanced engineering, digital intelligence, and world-class field expertise to reduce risk, improve performance, and maximize the value of customer assets. Together, we elevate every operation, delivering stronger wells, sharper decisions, and better energy for the world. Visit weatherford.com for more information and connect with us on social media.

Forward-Looking Statements

This release, as well as other statements we make, includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements that are not historical facts, including statements about Weatherford’s beliefs, plans, estimates, or expectations, are forward-looking statements. Forward-looking statements often use words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “plan,” “potential,” “should,” “target,” “will,” and other words of similar meaning. Such forward-looking statements include, but are not limited to, statements regarding the Redomestication, the related restructuring activities and the expected timing and financial implications. These statements are based on current beliefs, plans, estimates, and expectations, all of which involve risk and uncertainty. Actual results may differ materially from those included in such forward-looking statements and therefore you should not place undue reliance on them.

The factors that could cause actual results to differ materially from current expectations include, but are not limited to, our ability to realize the expected benefits from the Redomestication; the occurrence of difficulties in connection with the Redomestication, including any costs related thereto; the risk that the Redomestication disrupts current plans and operations; any changes in tax laws, tax treaties or tax regulations or the interpretation or enforcement thereof by the tax authorities in Ireland, the United States and other jurisdictions following the Redomestication; and the future financial performance of Weatherford following the Redomestication.

The foregoing factors are in addition to those other risks, uncertainties, and factors included in the “Risk Factors” section and elsewhere in Weatherford’s reports filed with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and other documents filed with the SEC. There may be other risks and uncertainties that we are not currently aware of or are unable to predict and which may also affect Weatherford’s forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements made in this communication are made only as of the date hereof or as of the dates indicated in the forward-looking statements and Weatherford undertakes no obligation to update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.

For Investors:
Luke Lemoine
Senior Vice President, Corporate Development & Investor Relations
+1 713-836-7777
investor.relations@weatherford.com

For Media:
Kelley Hughes
Vice President, Communications, Marketing & Sustainability
media@weatherford.com

NEW YORK, Nov. 13, 2026 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Decibel Cannabis Company Inc (TSX-V: DB; OTCQX: DBCCF), a global consumer-focused cannabis company, has qualified to trade on the OTCQX® Best Market. Decibel Cannabis Company Inc upgraded to OTCQX from the OTCQB® Venture Market.

Decibel Cannabis Company Inc begins trading today on OTCQX under the symbol “DBCCF.”  U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

Decibel Cannabis Company Inc is a market leader in Canadian branded manufactured cannabis products and global medical exports, built on leading brands including General Admission, Qwest and Standard Issue. The Company focuses on disciplined innovation, consistent product quality and strong brand execution. Alongside its leadership position in Canada, Decibel is a significant and growing participant in international cannabis markets.

The OTCQX Market is designed for established, investor-focused U.S. and international companies. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws. Graduating to the OTCQX Market from the OTCQB Market marks an important milestone for companies, enabling them to demonstrate their qualifications and build visibility among U.S. investors.

“We’re excited to begin trading on the OTCQX Best Market. It’s a great step for Decibel and a strong way to reach more U.S. investors. We look forward to welcoming new shareholders and sharing our story with a wider audience.”
      –    Benjamin Sze, Chief Executive Officer

Trading in non-U.S. North American securities on OTC Markets reached $29.38B in the third quarter of 2026, representing an 84.22% increase over Q3 2025. OTC Markets recorded $203.47B in total dollar volume in Q3. North America ranked among the top home markets by trading volume during the quarter, highlighting sustained U.S. investor demand for internationally listed names.

About Decibel Cannabis Company Inc

Decibel Cannabis Company Inc is a market leader in Canadian branded manufactured cannabis products and global medical exports, built on leading brands including General Admission, Qwest and Standard Issue. The Company focuses on disciplined innovation, consistent product quality and strong brand execution. Alongside its leadership position in Canada, Decibel is a significant and growing participant in international cannabis markets. Decibel operates a processing and manufacturing facility in Calgary, Alberta, a cultivation facility in Battleford, Saskatchewan, and an EU GMP licensed cultivation and processing facility in Chatham, Ontario.

About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our public markets: OTCQX® Best Market, OTCQB® Venture Market, OTCID™ Basic Market and Pink Limited™ Market. Our OTC Link® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets.

OTC Link ATS, OTC Link ECN, OTC Link NQB, OTC Overnight® and MOON ATS® are each an SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC.

To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

Media Contact:
OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com

NEW YORK, Nov. 13, 2026 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Decibel Cannabis Company Inc (TSX-V: DB; OTCQX: DBCCF), a global consumer-focused cannabis company, has qualified to trade on the OTCQX® Best Market. Decibel Cannabis Company Inc upgraded to OTCQX from the OTCQB® Venture Market.

Decibel Cannabis Company Inc begins trading today on OTCQX under the symbol “DBCCF.”  U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

Decibel Cannabis Company Inc is a market leader in Canadian branded manufactured cannabis products and global medical exports, built on leading brands including General Admission, Qwest and Standard Issue. The Company focuses on disciplined innovation, consistent product quality and strong brand execution. Alongside its leadership position in Canada, Decibel is a significant and growing participant in international cannabis markets.

The OTCQX Market is designed for established, investor-focused U.S. and international companies. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws. Graduating to the OTCQX Market from the OTCQB Market marks an important milestone for companies, enabling them to demonstrate their qualifications and build visibility among U.S. investors.

“We’re excited to begin trading on the OTCQX Best Market. It’s a great step for Decibel and a strong way to reach more U.S. investors. We look forward to welcoming new shareholders and sharing our story with a wider audience.”
      –    Benjamin Sze, Chief Executive Officer

Trading in non-U.S. North American securities on OTC Markets reached $29.38B in the third quarter of 2026, representing an 84.22% increase over Q3 2025. OTC Markets recorded $203.47B in total dollar volume in Q3. North America ranked among the top home markets by trading volume during the quarter, highlighting sustained U.S. investor demand for internationally listed names.

About Decibel Cannabis Company Inc

Decibel Cannabis Company Inc is a market leader in Canadian branded manufactured cannabis products and global medical exports, built on leading brands including General Admission, Qwest and Standard Issue. The Company focuses on disciplined innovation, consistent product quality and strong brand execution. Alongside its leadership position in Canada, Decibel is a significant and growing participant in international cannabis markets. Decibel operates a processing and manufacturing facility in Calgary, Alberta, a cultivation facility in Battleford, Saskatchewan, and an EU GMP licensed cultivation and processing facility in Chatham, Ontario.

About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our public markets: OTCQX® Best Market, OTCQB® Venture Market, OTCID™ Basic Market and Pink Limited™ Market. Our OTC Link® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets.

OTC Link ATS, OTC Link ECN, OTC Link NQB, OTC Overnight® and MOON ATS® are each an SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC.

To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

Media Contact:
OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com

Marshall Bernes to Retire from Corporate Role and Continue Serving on Board of Directors

EL MONTE, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) — GigaCloud Technology Inc (Nasdaq: GCT) (“GigaCloud” or the “Company”), a pioneer of global end-to-end B2B ecommerce technology solutions for large parcel merchandise, today announced the appointment of Sarah Anzalone as Head of Brand Center, effective November 30, 2026. Ms. Anzalone joined GigaCloud in September 2026 and has since worked alongside Marshall Bernes, whom she will succeed upon his planned retirement from the role on the same date. Mr. Bernes’ retirement was previously announced by the Company in April.

Over the past three years, Mr. Bernes has played a key role in developing the Company’s Brand Center, drawing on his extensive experience in the home furnishings industry to cultivate brand partnerships, expand product offerings, and support the integration of Noble House. After retiring from his corporate role, Mr. Bernes will continue serving on GigaCloud’s Board of Directors through August 17, 2027, ahead of the fifth anniversary of the Company’s initial public offering.

“We are grateful for Marshall’s leadership and contributions to GigaCloud and look forward to his continued guidance as a member of our Board,” said Larry Wu, Founder and Chief Executive Officer of GigaCloud. “At the same time, we are pleased to have Sarah step into this role. Her expertise in product development and portfolio strategy will be instrumental in strengthening our brand collection and aligning our offerings with evolving market demand.”

Ms. Anzalone brings to GigaCloud over a decade of experience in the furniture industry. Prior to joining the Company, she served as Senior Director of Product Development at Simpli Home and Executive Director at eSolutions Furniture, where she led multidisciplinary teams across design, engineering, product development and portfolio strategy. Her expertise spans global furniture markets, emerging design trends and consumer insights, translating market opportunities into business growth. In her new role, Ms. Anzalone will lead GigaCloud’s Brand Center, focusing on brand development, product portfolio strategy and expanding and diversifying the Company’s product offerings.

“I look forward to building on the progress we have made and working with the team to further strengthen our brand portfolio and drive continued growth,” said Ms. Anzalone.

About GigaCloud Technology Inc
GigaCloud Technology Inc is a pioneer of global end-to-end B2B technology solutions for large parcel merchandise. The Company’s B2B ecommerce platform, which it refers to as the “GigaCloud Marketplace,” integrates everything from discovery and payments to logistics tools into one easy-to-use platform. The Company’s global marketplace seamlessly connects manufacturers, primarily in Asia, with resellers, primarily in the U.S., Asia and Europe, to execute cross-border transactions with confidence, speed and efficiency. The Company offers a truly comprehensive solution that transports products from the manufacturer’s warehouse to the end customer’s doorstep, all at one fixed price. The Company first launched its marketplace in January 2019 by focusing on the global furniture market and has since expanded into additional categories such as home appliances and fitness equipment. For more information, please visit the Company’s website: https://investors.gigacloudtech.com/.

For investor and media inquiries, please contact:

GigaCloud Technology Inc
Investor Relations – ir@gigacloudtech.com

PondelWilkinson Inc.
Todd Kehrli (Investors) – tkehrli@pondel.com
Laurie Berman (Investors) – lberman@pondel.com
George Medici (Media) – gmedici@pondel.com

Marshall Bernes to Retire from Corporate Role and Continue Serving on Board of Directors

EL MONTE, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) — GigaCloud Technology Inc (Nasdaq: GCT) (“GigaCloud” or the “Company”), a pioneer of global end-to-end B2B ecommerce technology solutions for large parcel merchandise, today announced the appointment of Sarah Anzalone as Head of Brand Center, effective November 30, 2026. Ms. Anzalone joined GigaCloud in September 2026 and has since worked alongside Marshall Bernes, whom she will succeed upon his planned retirement from the role on the same date. Mr. Bernes’ retirement was previously announced by the Company in April.

Over the past three years, Mr. Bernes has played a key role in developing the Company’s Brand Center, drawing on his extensive experience in the home furnishings industry to cultivate brand partnerships, expand product offerings, and support the integration of Noble House. After retiring from his corporate role, Mr. Bernes will continue serving on GigaCloud’s Board of Directors through August 17, 2027, ahead of the fifth anniversary of the Company’s initial public offering.

“We are grateful for Marshall’s leadership and contributions to GigaCloud and look forward to his continued guidance as a member of our Board,” said Larry Wu, Founder and Chief Executive Officer of GigaCloud. “At the same time, we are pleased to have Sarah step into this role. Her expertise in product development and portfolio strategy will be instrumental in strengthening our brand collection and aligning our offerings with evolving market demand.”

Ms. Anzalone brings to GigaCloud over a decade of experience in the furniture industry. Prior to joining the Company, she served as Senior Director of Product Development at Simpli Home and Executive Director at eSolutions Furniture, where she led multidisciplinary teams across design, engineering, product development and portfolio strategy. Her expertise spans global furniture markets, emerging design trends and consumer insights, translating market opportunities into business growth. In her new role, Ms. Anzalone will lead GigaCloud’s Brand Center, focusing on brand development, product portfolio strategy and expanding and diversifying the Company’s product offerings.

“I look forward to building on the progress we have made and working with the team to further strengthen our brand portfolio and drive continued growth,” said Ms. Anzalone.

About GigaCloud Technology Inc
GigaCloud Technology Inc is a pioneer of global end-to-end B2B technology solutions for large parcel merchandise. The Company’s B2B ecommerce platform, which it refers to as the “GigaCloud Marketplace,” integrates everything from discovery and payments to logistics tools into one easy-to-use platform. The Company’s global marketplace seamlessly connects manufacturers, primarily in Asia, with resellers, primarily in the U.S., Asia and Europe, to execute cross-border transactions with confidence, speed and efficiency. The Company offers a truly comprehensive solution that transports products from the manufacturer’s warehouse to the end customer’s doorstep, all at one fixed price. The Company first launched its marketplace in January 2019 by focusing on the global furniture market and has since expanded into additional categories such as home appliances and fitness equipment. For more information, please visit the Company’s website: https://investors.gigacloudtech.com/.

For investor and media inquiries, please contact:

GigaCloud Technology Inc
Investor Relations – ir@gigacloudtech.com

PondelWilkinson Inc.
Todd Kehrli (Investors) – tkehrli@pondel.com
Laurie Berman (Investors) – lberman@pondel.com
George Medici (Media) – gmedici@pondel.com